Stockreport
Pruritus Therapeutics Market Analysis and Forecast 2025-2034 | Biologics and JAK Inhibitors Drive Innovation in Pruritus Care, Offering Targeted Relief and Long-term Efficacy [Yahoo! Finan...
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Dublin, April 16, 2025 (GLOBE NEWSWIRE) -- The "Pruritus Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The Global Pruritus Therapeutics Market reached USD 9.6 billion in 2024 and is projected to grow at a CAGR of 4.2% between 2025 and 2034. The rising incidence of chronic itching disorders, driven by conditions such as atopic dermatitis, psoriasis, and chronic kidney disease, continues to fuel market expansion. As pruritus remains a common yet often challenging symptom to treat, the demand for advanced therapeutic solutions is accelerating. The increasing burden of dermatologic and systemic conditions worldwide is compelling pharmaceutical companies to innovate and expand their treatment portfolios. The growing geriatric population, a demographic highly susceptible to chronic pruritus, further amplifies market demand. Additionally, heightened awareness regarding availab
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Exploring Growth Trends in the Chemotherapy Induced Anemia Market: A Surge to USD 4.84 Billion by 2032 [Yahoo! Finance][Yahoo! Finance]
- Amgen (NASDAQ:AMGN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from[MarketBeat]
- FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease [Yahoo! Finance][Yahoo! Finance]
- Amgen (NASDAQ:AMGN) was given a new $304.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More